When compared to the non-ICAS group, patients in the ICAS group had a larger VAT/SAT ratio (1.15 ± 0.30 vs. 0.89 ± 0.25, p < 0.001), a greater prevalence of NAFLD (37.9% vs. 19.8%, p = 0.007), a higher prevalence of diabetes (55.8% vs. 30.8%, p = 0.001), higher elevated fibrinogen levels (2.96 ± 1.03 vs. 2.55 ± 0.77, p = 0.002), and lower adiponectin levels (2.43 ± 0.99 vs. 3.36 ± 1.27, p < 0.001). This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.